Monitoring latent viral reactivation in critically ill patients: a review of immunopathology and emerging diagnostics

Background Critical illness, particularly sepsis, is characterized by dynamic immune dysregulation in which inflammation and immunosuppressive features coexist. This state may permit reactivation of latent viruses and provides a potential window into host immune competence. This review evaluates latent viral reactivation as an endogenous immunobiological probe in ICU patients and discusses the emerging role of quantitative molecular monitoring. Mechanisms and clinical relevance Lymphocyte depletion, T-cell exhaustion, monocyte dysfunction, reduced antigen presentation, and stress-mediated viral gene regulation contribute to impaired antiviral immune surveillance. Reactivation of cytomegalovirus, Epstein-Barr virus, herpes simplex virus, human herpesvirus 6, parvovirus B19, and changes in Torque teno virus load have been described in critically ill patients. Multi-virus co-detection and high viral loads may reflect more profound immune dysregulation, although causality and clinically actionable thresholds remain uncertain. Methodological evolution Conventional qPCR remains widely used for clinical viral-load testing, but interpretation is affected by specimen type, target selection, standardization, and low-copy precision. Droplet digital PCR may support absolute quantification, low-abundance detection, and multiplex longitudinal monitoring, but its performance depends on template input, extraction efficiency, assay design and detection thresholds, and it requires careful validation of dynamic range, inhibition controls, over-range reporting, and clinical thresholds. Conclusions Latent viral reactivation should be interpreted as a dynamic immune-viral signal rather than a simple positive or negative event. TTV is best positioned as a continuous load-based marker of net immune control, while herpesvirus reactivation may help identify specific patterns of impaired antiviral surveillance. ddPCR offers a promising research platform for quantitative immune-viral phenotyping, but further longitudinal validation is needed before routine ICU implementation.